Immix Biopharma’s (IMMX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Immix Biopharma (NASDAQ:IMMX) in a research report released on Thursday morning, Benzinga reports. The brokerage currently has a $7.00 target price on the stock.

Immix Biopharma Stock Performance

IMMX opened at $1.63 on Thursday. The firm’s fifty day moving average is $1.93 and its 200 day moving average is $2.19. The stock has a market cap of $43.05 million, a price-to-earnings ratio of -1.75 and a beta of 0.12. Immix Biopharma has a fifty-two week low of $1.26 and a fifty-two week high of $7.75.

Immix Biopharma (NASDAQ:IMMX) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.06. On average, equities research analysts predict that Immix Biopharma will post -0.64 earnings per share for the current year.

Hedge Funds Weigh In On Immix Biopharma

A hedge fund recently raised its stake in Immix Biopharma stock. Tocqueville Asset Management L.P. raised its stake in Immix Biopharma, Inc. (NASDAQ:IMMX) by 89.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 37,800 shares of the company’s stock after acquiring an additional 17,800 shares during the period. Tocqueville Asset Management L.P. owned approximately 0.14% of Immix Biopharma worth $116,000 as of its most recent SEC filing. Institutional investors and hedge funds own 11.26% of the company’s stock.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.